EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Uncovering resistance pathways to first- and last-line antibiotics in Mycobacterium tuberculosis populations

Prapaporn Srilohasin, Jasmine M Williams, Aidan P Tay, Brodie F Gillieatt, Daniel R Pascoe, Ram P Maharjan, Angkana Chaipraset, Pravech Ajawatanawong, Amy K Cain

Microbial Genomics · 19.05.2026 · 12 (5)

DOI: 10.1099/mgen.0.001723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Genomics, erschienen am 19.05.2026. Verfasst von Prapaporn Srilohasin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Drug Resistance, Bacterial, Antitubercular Agents. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ARC Linkage Infrastructure Grant, Australian Government Research Training Program Scholarship, ARC Future Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB), caused by Mycobacterium tuberculosis , is one of the world’s deadliest diseases, currently responsible for ~1.5 million deaths per year and rising. Recently, rifampicin-resistant M. tuberculosis was designated as a critical priority pathogen status by the World Health Organization. However, few controlled laboratory studies are available that systematically assess the molecular drivers of antibiotic resistance development in TB. In this study, we paired laboratory-directed evolution and population-level deep-sequencing approaches to map the evolutionary pathways taken by M. tuberculosis to develop resistance to first- and last-line therapies (rifampicin and linezolid) and then characterized de novo resistance mutation occurrence over time. We demonstrated that the majority of M. tuberculosis populations readily acquire mutations in genes commonly found in rifampicin- and linezolid-resistant clinical isolates ( rpoB and rplC ). However, we also identified mutations in six genes, mostly present in subpopulations (17–41%) and not previously linked to rifampicin or linezolid resistance, including four associated with rifampicin resistance ( Rv0052 , ppsD , ppsE and mptC ) and two associated with linezolid resistance ( glpK and echA12 ). The ppsD , glpK and mptC mutations were also identified in published individual sequencing reads of antibiotic-resistant clinical isolates. Further investigation of the identified resistance determinants ppsD / E established that mutations in these genes appear to mediate resistance across multiple species, with an Escherichia coli mutant of the ortholog ( fabF ), representing a shared domain featured in PpsD and PpsE, phenotypically displaying increased antibiotic tolerance to low-level rifampicin. This study highlights the power of using controlled laboratory studies to uncover minority variants in populations of M. tuberculosis . These outcomes will lead to improved diagnosis of antibiotic resistance emergence in TB, to optimize management and treatment of TB infections, and ultimately to minimize patient deaths.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisDrug Resistance, BacterialAntitubercular AgentsRifampinLinezolidMutationHumansBacterial ProteinsMicrobial Sensitivity TestsDirected Molecular Evolution

Stichwörter der Autor:innen

Mycobacterium tuberculosisantibiotic resistancedirected evolutionlinezolidrifampicintuberculosis

Substanzen

RifampinLinezolidAntitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • School of Natural Sciences, Macquarie University, Sydney, NSW, Australia.
  • ARC Centre of Excellence in Synthetic Biology, Macquarie University, Sydney, NSW, Australia.
  • Australian Genome Foundry, Macquarie University, Sydney, NSW, Australia.

Förderung

  • ARC Linkage Infrastructure Grant
  • Australian Government Research Training Program Scholarship
  • ARC Future Fellowship
  • Mahidol University-MQ Research Seed Grant

Zitieren

APA

Srilohasin, P., Williams, J. M., Tay, A. P., Gillieatt, B. F., Pascoe, D. R., Maharjan, R. P., Chaipraset, A., Ajawatanawong, P., & Cain, A. K. (2026). Uncovering resistance pathways to first- and last-line antibiotics in Mycobacterium tuberculosis populations. Microbial Genomics, 12(5). https://doi.org/10.1099/mgen.0.001723

Vancouver

Srilohasin P, Williams JM, Tay AP, Gillieatt BF, Pascoe DR, Maharjan RP, et al. Uncovering resistance pathways to first- and last-line antibiotics in Mycobacterium tuberculosis populations. Microbial Genomics. 2026;12(5). doi:10.1099/mgen.0.001723

BibTeX
@article{Srilohasin2026,
  author = {Srilohasin, Prapaporn and Williams, Jasmine M and Tay, Aidan P and Gillieatt, Brodie F and Pascoe, Daniel R and Maharjan, Ram P and Chaipraset, Angkana and Ajawatanawong, Pravech and Cain, Amy K},
  title = {Uncovering resistance pathways to first- and last-line antibiotics in Mycobacterium tuberculosis populations},
  journal = {Microbial Genomics},
  year = {2026},
  volume = {12},
  number = {5},
  doi = {10.1099/mgen.0.001723}
}
Kostenlos starten →